A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

NCT00136461 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Acute Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: All-trans retinoic acid
DRUG: Bryostatin 1

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]